<DOC>
	<DOCNO>NCT00251381</DOCNO>
	<brief_summary>The purpose study determine 1-year rate locoregional disease control experimental arm , use control arm avoid selection bias .</brief_summary>
	<brief_title>Cetuximab &amp; Concomitant-Boost Accelerated RT Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma .</brief_title>
	<detailed_description>- To determine 1-year rate locoregional disease control experimental arm , use control arm avoid selection bias . - To determine 2 3 year rate locoregional disease control . - To evaluate safety toxicity combination cetuximab concomitant-boost accelerate radiotherapy follow 12 week complementary treatment cetuximab . Both acute chronic toxicity assess . - To determine specific disease-free survival , event-free survival , disease-specific survival overall survival - To determine acute late toxicity - To determine EGFR , p53 , Ki67 , evaluate value prognostic factor .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Written inform consent . Aged 18 80 , inclusive . Karnofsky functional status &gt; = 70 % time enrolment study . Life expectancy 3 month . Histologically confirm diagnosis oropharyngeal squamous cell carcinoma : base tongue , vallecula , tonsil tonsillar fossa pillar , glossotonsillar sulcus , inferior surface soft palate , uvula lateral posterior oropharyngeal wall . Stage III IV evidence distant metastasis ( IVA IV B ) Patients medical condition receive radical concomitantboost accelerate radiotherapy treatment . Neutrophils &gt; = 1500/ mm3 , platelet count &gt; = 100 000/ mm3 haemoglobin &gt; = 10 g/ dL . Proper liver function : total bilirubin &lt; = 1.5 x upper limit normal ( ULN ) ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; = 2.5 x ULN . Proper renal function : serum creatinine &lt; = 1.5 x ULN ; value &gt; 1.5 x ULN , creatinine clearance &gt; = 55 ml/min . Serum calcium within normal limit . Adequate nutritional state : weight loss &lt; 20 % respect usual weight serum albumin &gt; 35 g/l . Effective birth control method possibility conception and/or pregnancy . Availability tumour tissue immunohistochemical analysis EGFR expression . Metastatic disease . Previous surgical , radiotherapy and/or chemotherapy treatment disease study . Other nonoropharyngeal tumour site head neck area . Other previous and/or simultaneous squamous cell carcinoma . Diagnosis cancer previous 5 year , except properly treat carcinoma situ uterine cervix and/or basal cell skin carcinoma . Active infection ( infection require intravenous antibiotic ) , include active tuberculosis diagnose HIV . Uncontrolled hypertension define systolic blood pressure &gt; = 180 mm Hg and/or diastolic blood pressure &gt; = 130 mm Hg rest . Pregnancy ( absence pregnancy must confirm serumHCG test ) breastfeed woman . Chronic , concomitant systemic immunotherapy , hormonal treatment cancer . Other concomitant anticancer treatment . Clinically significant coronary artery disease , history myocardial infarction previous 12 month high risk control arrhythmia cardiac insufficiency . Chronic obstructive pulmonary disease may require &gt; 3 hospitalisation previous 12 month . Out control active peptic ulcer . Presence psychological medical illness might impede patient carry study give signature inform consent Known drug abuse ( exception excessive alcohol consumption ) Known allergic reaction component treatment study . Previous treatment monoclonal antibody signal transduction inhibitor EGFRtargeted treatment . Any experimental treatment 30 day prior enrolment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Oropharyngeal Neoplasms</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Concomitant-boost accelerate radiotherapy</keyword>
</DOC>